Please try another search
Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan.
Name | Age | Since | Title |
---|---|---|---|
Koki Uehara | 47 | 2012 | President & Representative Director |
Kiyoshi Nagata | 70 | 2018 | Director |
Toshimitsu Hayashi | 43 | 2022 | GM of Pharmaceutical Affairs & Clinical Development Department and Director |
Kazumitsu Yabu | 65 | 2003 | Director |
Kohei Tsujii | 46 | 2018 | Independent Outside Director |
Tomoyuki Asano | 53 | 2007 | Chairman |
Takahiro Kido | 51 | 2022 | GM of Corporate Planning Department & Director |
Masaya Onishi | 50 | 2018 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review